Aethlon Medical Yönetim

Yönetim kriter kontrolleri 4/4

Aethlon Medical CEO'su Jim Frakes, Jan2008 tarihinde atandı, in görev süresi 16.83 yıldır. in toplam yıllık tazminatı $ 416.45K olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.017% ine doğrudan sahiptir ve bu hisseler $ 937.79 değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 7 yıldır.

Anahtar bilgiler

Jim Frakes

İcra Kurulu Başkanı

US$416.4k

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	16.8yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	7yrs

Son yönetim güncellemeleri

Recent updates

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Aug 02

FDA approves protocol change in Aethlon's trial of its purifier to treat severe COVID

Jul 11

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Mar 18

We're Interested To See How Aethlon Medical (NASDAQ:AEMD) Uses Its Cash Hoard To Grow

Nov 09

Aethlon Medical (AEMD) rockets 63% as FDA amends Hemopurifier IDE for COVID-10 treatment

Dec 16

Aethlon names Charles J. Fisher, Jr., M.D. as CEO

Nov 03

CEO Tazminat Analizi

Jim Frakes'un ücretlendirmesi Aethlon Medical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$11m
Jun 30 2024	n/a	n/a	-US$11m
Mar 31 2024	US$416k	US$416k	-US$12m
Dec 31 2023	n/a	n/a	-US$12m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$12m
Dec 31 2022	n/a	n/a	-US$13m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$10m
Dec 31 2021	n/a	n/a	-US$9m
Sep 30 2021	n/a	n/a	-US$9m
Jun 30 2021	n/a	n/a	-US$9m
Mar 31 2021	US$582k	US$275k	-US$8m
Dec 31 2020	n/a	n/a	-US$7m
Sep 30 2020	n/a	n/a	-US$6m
Jun 30 2020	n/a	n/a	-US$6m
Mar 31 2020	US$355k	US$264k	-US$6m
Dec 31 2019	n/a	n/a	-US$6m
Sep 30 2019	n/a	n/a	-US$7m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	US$286k	US$256k	-US$6m
Dec 31 2018	n/a	n/a	-US$6m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	US$235k	US$235k	-US$6m

Tazminat ve Piyasa: Jim 'nin toplam tazminatı ($USD 416.45K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 647.72K ).

Tazminat ve Kazançlar: Jim 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jim Frakes (67 yo)

16.8yrs

Görev süresi

US$416,449

Tazminat

Mr. James B. Frakes, also known as Jim, M.B.A. has been the Chief Financial Officer at Aethlon Medical, Inc. since January 2008 and served as its Interim Chief Executive Officer since November 07, 2023 unt...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Frakes	CEO, CFO	16.8yrs	US$416.45k	0.017% $ 937.8
Guy Cipriani	Senior VP & COO	less than a year	US$378.06k	0.013% $ 708.9
Steven LaRosa	Chief Medical Officer	3.8yrs	US$430.00k	0% $ 0

3.8yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: AEMD 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
James Frakes	CEO, CFO	less than a year	US$416.45k	0.017% $ 937.8
Edward Broenniman	Independent Chairman of the Board	25.7yrs	US$147.50k	0.18% $ 10.2k
Nathan Levin	Member of Extracorporeal Therapy Advisory Board	no data	Veri yok	Veri yok
Gregory T. Kovacs	Member of Extracorporeal Therapy Advisory Board	no data	Veri yok	Veri yok
Claudio Ronco	Member of Extracorporeal Therapy Advisory Board	no data	Veri yok	Veri yok
Larry Cowgill	Member of Sepsis & Inflammation Advisory Board	no data	Veri yok	Veri yok
John Kellum	Member of Extracorporeal Therapy Advisory Board	no data	Veri yok	Veri yok
Chetan Shah	Independent Director	11.4yrs	US$113.75k	0.15% $ 8.5k
David Ward	Member of Extracorporeal Therapy Advisory Board	no data	Veri yok	Veri yok
Irshad Chaudry	Member of Sepsis & Inflammation Advisory Board	no data	Veri yok	Veri yok
Geert Schmid-Schönbein	Member of Sepsis & Inflammation Advisory Board	no data	Veri yok	Veri yok
Angela Rossetti	Independent Director	2.6yrs	US$113.00k	0.18% $ 9.9k

7.0yrs

Ortalama Görev Süresi

69yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AEMD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7 yıldır).

Aethlon Medical Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Aethlon Medical, Inc., Annual General Meeting, Sep 27, 2024

Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2023

Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2022

Insufficient new directors

Recent updates

Price target decreased by 45% to US$3.85

New major risk - Revenue and earnings growth

Aethlon Medical Announces Enrollment of the First Patient in (FPI) Its Hemopurifier Cancer Trial in Australia

Aethlon Medical, Inc. to Report Q2, 2025 Results on Nov 13, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier Cancer Trial in India

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical, Inc. Announces Publication of Preclinical Data Showing Ability of the Hemopurifier to Remove Extracellular Vesicles and MicroRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Donor Kidneys

Aethlon Medical, Inc., Annual General Meeting, Sep 27, 2024

Aethlon Medical, Inc. Receives Second Ethics Committee Approval for Hemopurifier Cancer Trial

Aethlon Medical, Inc. to Report Q1, 2025 Results on Aug 14, 2024

Aethlon Medical, Inc. to Report Fiscal Year 2024 Results on Jun 27, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

Aethlon Medical, Inc. Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies

New major risk - Shareholder dilution

Aethlon Medical, Inc. has completed a Follow-on Equity Offering in the amount of $4.69235 million.

New major risk - Share price stability

Aethlon Medical, Inc. Reports Positive Results from an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles from Cancer Patient Plasma

Aethlon Medical, Inc. has filed a Follow-on Equity Offering in the amount of $16.32 million.

Price target increased by 27% to US$40.10

Aethlon Medical, Inc. to Report Q3, 2024 Results on Feb 14, 2024

New major risk - Financial position

Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer

Aethlon Medical, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Price target decreased by 21% to US$31.55

Price target decreased by 90% to US$4.01

Aethlon Medical, Inc. Receives Clearance from Drug Controller General of India for Potential Phase 1 Trial of its Hemopurifier(R) in Oncology

Aethlon Medical, Inc. to Report Q1, 2024 Results on Aug 10, 2023

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2023

Price target decreased by 12% to US$6.50

Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee

New major risk - Shareholder dilution

Full year 2023 earnings released: US$0.59 loss per share (vs US$0.71 loss in FY 2022)

Aethlon Medical, Inc. to Report Q4, 2023 Results on Jun 28, 2023

New major risk - Share price stability

No longer forecast to breakeven

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2022)

Aethlon Medical, Inc. to Report Q3, 2023 Results on Feb 13, 2023

Forecast to breakeven in 2023

No longer forecast to breakeven

First half 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 1H 2022)

Aethlon Medical, Inc. to Report Q2, 2023 Results on Nov 14, 2022

Aethlon Medical Receives Non-Compliance Notice of Delisting from Nasdaq

Aethlon Medical, Inc. Announces Early Feasibility Study of the Hemopurifier

Forecast to breakeven in 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aethlon Medical, Inc. to Report Q1, 2023 Results on Aug 09, 2022

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2022

Aethlon Medical, Inc. Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment

FDA approves protocol change in Aethlon's trial of its purifier to treat severe COVID

Consensus revenue estimates fall by 100%

Aethlon Medical, Inc. to Report Fiscal Year 2022 Results on Jun 28, 2022

Price target decreased to US$7.00

Consensus revenue estimates increase by 178%

Insufficient new directors

Consensus revenue estimates increase by 178%

Aethlon Medical, Inc. Announces Executive Changes

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Consensus revenue estimates fall by 68%

Aethlon Medical, Inc. to Report Q3, 2022 Results on Feb 14, 2022

Insufficient new directors

We're Interested To See How Aethlon Medical (NASDAQ:AEMD) Uses Its Cash Hoard To Grow

Consensus revenue estimates fall to US$1.24m

Full year 2021 earnings released: US$0.65 loss per share (vs US$1.87 loss in FY 2020)

Aethlon Medical climbs on Reddit interest

Aethlon Medical, Inc. Publishes Case Studies of Two Critically ill Covid-19 Patients Treated with the Hemopurifier®

Forecast to breakeven in 2023

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate